Candel reports positive final Phase 2a data for CAN-2409 in NSCLC; mOS 24.5 months, long survival tail

Candel Therapeutics, Inc.

mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.
In patients with progressive disease at baseline (cohort 2, n=41), mOS was 21.5 months, vs. 9.8–11.8 months for docetaxel.
37% (15/41) of progressive disease patients alive >24 months; long tail of survival observed.
In non-squamous NSCLC (n=33), mOS was 25.4 months; ITT analysis showed 16.7 months vs. 9.9–12.3 months for SOC.
Systemic anti-tumor response (abscopal effect) seen in 69% of patients with multiple lesions; safety profile favorable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.